Premium
The precancerous stem cells can be a common progenitor for cancer cells and mesenchymal supporting cells in malignant tumors
Author(s) -
Shen Rulong,
Chen Li,
Gao JianXin
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a217-c
Subject(s) - cancer stem cell , cancer research , stem cell , progenitor cell , cancer cell , mesenchymal stem cell , cancer , biology , stromal cell , pathology , angiogenesis , medicine , microbiology and biotechnology , genetics
A solid tumor is composed of cancer cells, blood vessels, and supporting stromas, which determine its growth rate and malignancy. However, the origin of the various components of tumor is largely unknown. Recently we have established several precancerous stem cell (pCSC) clones from the spleen of a p53−/−Stat‐1−/− mouse with dendritic cell‐like lymphoma, which have the bi‐potency of benign and malignant differentiation. Based on the finding, we develop a pCSC line stably expressing eGFPs to explore the contribution of the pCSCs to tumor components. The eGFP+ or eGFP‐ pCSCs were injected i.p. or s.c. into the SCID mice. The pCSCs progressed to solid tumors in about 40 ~ 70% recipients, depending on experiments. Histological analysis revealed that the eGFP+ cells contributed to the cancer cells, blood vessels and supporting stroma. Correspondingly, the pCSC‐derived endothelia, skeletal muscle cells and lipoblasts, etc., were identified by the antibody to neomycin, which is a product of the neomycin gene integrated to genome DNA of pCSCs. Our results have revealed for the first time that pCSCs can be a common progenitor for cancer cells, blood vessel cells and stromal cells. Therefore, pCSCs are a novel target to prevent malignant cell differentiation, angiogenesis and stromal formation. The pCSC lines established in our laboratory can be used for anti‐cancer drug development.